Document is current
Any future updates will be listed below
-
Authors
Huemer, Florian https://orcid.org/0000-0001-9184-4038
Weiss, Lukas https://orcid.org/0000-0002-2174-5613
-
Funding
Funding for this research was provided by:
Paracelsus Medical University
- License Information
-
More Information
Article History
Received: 14 December 2025
Accepted: 1 March 2026
First Online: 20 March 2026
Conflict of interest
: F. Huemer: Honoraria—Lilly, Pierre Fabre, Amgen, Servier, Daiichi Sankyo, BMS, Merck, Sanofi, Roche, Janssen, Astellas, Pharmamar; Johnson & Johnson; Travel support—Servier, BMS, Roche, Merck, Pharmamar, Pfizer, Pierre Fabre, Sanofi, Daiichi Sankyo, Gilead, Jazz Pharmaceuticals; Stock and other ownership: Guardant Health, Natera, Revolution Medicines. L. Weiss: Honoraria—Amgen, Astellas, BMS, Daiichi Sankyo, Deciphera, Lilly, Merck, MSD, Novocure, Pierre Fabre, Roche, Servier, Takeda; Travel support—Astra Zeneca, Merck, Pfizer, Pierre Fabre, Roche, Servier; Advisory board—Amgen, Astellas, BMS, Deciphera, GSK, Incyte, Lilly, Merck, MSD, Novocure, PharmaMar, Pierre Fabre, Roche, Takeda; Leadership—Austrian Breast and Colorectal Study Group (ABCSG); Stock and other ownership—Guardant Health; Research support—Novocure, Roche.
